FIELD: chemistry.
SUBSTANCE: invention relates to biotechnology and immunology. Invention discloses a monoclonal antibody and its antigen-binding parts which specifically bind the C-end or central part of the macrophage migration inhibitory factor (MIF). The anti-MIF antibody and its antigen-binding part further inhibit biological function of the human MIF. The invention also describes an isolated heavy and light chain of immunoglobulins obtained from anti-MIF antibodies, and molecules of nucleic acids which encode such immunoglobulins.
EFFECT: disclosed is a method of identifying anti-MIF antibodies, pharmaceutical compositions containing said antibodies and a method of using said antibodies and compositions for treating diseases associated with MIF.
22 cl, 14 dwg, 16 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MONOCLONAL ANTIBODIES AND METHODS OF USING THEM | 2017 |
|
RU2694412C2 |
| MONOCLONAL ANTIBODY WHICH SPECIFICALLY BINDS GITR | 2019 |
|
RU2734432C1 |
| BINDING MOLECULES SPECIFIC TO IL-21, AND FIELD OF APPLICATION THEREOF | 2015 |
|
RU2708336C2 |
| MONOCLONAL ANTIBODIES WHICH SPECIFICALLY BIND TO THE BETA-CHAIN REGION OF THE TRBV-9 FAMILY OF THE HUMAN T-CELL RECEPTOR, AND METHODS FOR USE THEREOF | 2018 |
|
RU2711871C1 |
| MONOCLONAL PD-L1 ANTIBODY | 2017 |
|
RU2665790C1 |
| ANTI-PD-1 ANTIBODIES, METHOD FOR THEIR PRODUCTION, AND METHOD OF APPLICATION | 2016 |
|
RU2656181C1 |
| APPLICATION OF ANTI-CD40-ANTIBODIES | 2006 |
|
RU2442606C2 |
| PREVENTIVE AND THERAPEUTIC AGENT FOR INFLAMMATORY DISEASE | 2007 |
|
RU2511406C2 |
| ANTI-C5a ANTIBODIES AND THEIR APPLICATIONS | 2018 |
|
RU2773779C2 |
| NOVEL ANTI-IL13 ANTIBODIES AND USE THEREOF | 2004 |
|
RU2487887C2 |
